Illumina, Inc. logo

Illumina, Inc. (ILMN)

Market Open
27 Aug, 18:19
NASDAQ (NGS) NASDAQ (NGS)
$
99. 45
+0.72
+0.73%
$
15.65B Market Cap
- P/E Ratio
0% Div Yield
541,789 Volume
0.66 Eps
$ 98.73
Previous Close
Day Range
98.1 99.73
Year Range
68.7 156.66
Want to track ILMN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 64 days
Activist investor Keith Meister to join Illumina's board, WSJ reports

Activist investor Keith Meister to join Illumina's board, WSJ reports

Activist investor Keith Meister will join the board of gene-sequencing maker Illumina , and current board member Scott Gottlieb will become chairman, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.

Reuters | 5 months ago
Activist Investor Meister to Join Illumina's Board

Activist Investor Meister to Join Illumina's Board

Keith Meister's hedge fund Corvex Management has a 2.5% stake in the gene-sequencing machine maker.

Wsj | 5 months ago
Illumina's AGD Project Completes 250,000 Whole Genomes: Stock to Gain?

Illumina's AGD Project Completes 250,000 Whole Genomes: Stock to Gain?

ILMN-NashBio's AGD initiative achieves the milestone of completing 250,000 whole genomes.

Zacks | 5 months ago
Why Illumina (ILMN) is a Top Value Stock for the Long-Term

Why Illumina (ILMN) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 5 months ago
Illumina lowers outlook due to China sales ban, to cut $100 million in costs

Illumina lowers outlook due to China sales ban, to cut $100 million in costs

Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ban on imports of its genetic sequencing instruments.

Reuters | 5 months ago
Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban

Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban

Beijing banned imports of Illumina's gene-sequencing machines in response to U.S. tariffs.

Wsj | 5 months ago
Illumina Stock Drops as China Bans Imports of Gene-Sequencing Technology

Illumina Stock Drops as China Bans Imports of Gene-Sequencing Technology

Illumina was placed on China's list of ‘unreliable entities' in February.

Barrons | 5 months ago
China bans imports of Illumina's gene sequencers

China bans imports of Illumina's gene sequencers

China announced a ban on Tuesday on imports of genetic sequencers from U.S. medical equipment maker Illumina , just minutes after U.S. President Donald Trump's additional 10% tariff on Chinese goods took effect.

Reuters | 5 months ago
Here's Why Illumina (ILMN) is a Strong Value Stock

Here's Why Illumina (ILMN) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 6 months ago
Illumina, Inc. (ILMN) AGBT Investor Session Conference (Transcript)

Illumina, Inc. (ILMN) AGBT Investor Session Conference (Transcript)

Illumina, Inc. (NASDAQ:ILMN ) AGBT Investor Session Conference February 25, 2025 11:00 AM ET Company Participants Salli Schwartz - Head of Investor Relations Jacob Thaysen - Chief Executive Officer Steve Barnard - Chief Technology Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Subbu Nambi - Guggenheim Securities Dan Brennan - TD Cowen Dan Arias - Stifel Puneet Souda - SVB Securities Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies LLC Patrick Donnelly - Citi Tejas Savant - Morgan Stanley Jack Meehan - Nephron Research Kyle Mikson - Canaccord Genuity Salli Schwartz Welcome. Thank you for your patience while we got started.

Seekingalpha | 6 months ago
ILMN Stock Might Rise From Collaboration With Broad Clinical Labs

ILMN Stock Might Rise From Collaboration With Broad Clinical Labs

Illumina Collaborates with Broad Clinical Labs to set the standard for scalable single-cell research and accelerate discovery in areas such as disease modeling and drug development.

Zacks | 6 months ago
Here's Why Illumina (ILMN) is a Strong Growth Stock

Here's Why Illumina (ILMN) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 6 months ago
Loading...
Load More